Search results
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
Zacks via Yahoo Finance· 2 days agoCore earnings per share are also expected to increase in the low double-digit to low teens...
Merck raises 2024 profit forecast on strong cancer, HPV drugs sales
Reuters· 3 days ago, opens new tab on Thursday raised its annual profit and revenue forecast on the back of strong...
Cancer breakthrough as scientists develop jab that could provide miracle cure
Daily Express· 2 days agoA revolutionary skin cancer vaccine being tested on British patients offers hope of a cure for the...
Merck's Cancer Drug and Vaccine Sales Drive Better-Than-Expected Results
Investopedia· 3 days agoMerck (MRK) shares advanced in intraday trading Thursday after the pharmaceutical firm reported...
Merck Raises Forecast as Sales of Its Cancer Immune Therapy Soar
Bloomberg· 3 days agoMerck & Co. raised its annual profit and revenue forecast as the blockbuster cancer drug Keytruda...
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
Zacks via Yahoo Finance· 3 days agoThe Zacks Consensus Estimate for 2024 EPS has declined from $11.13 per share to $11.12 over the past...
Merck Earnings Preview: Strong quarter expectations on the back of core products' growth
Seeking Alpha· 4 days agoMerck (NYSE:MRK) is scheduled to announce Q1 earnings results on Thursday, April 25th, before market...
Merck (MRK) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 3 days agoSales in our Animal Health business increased 4% across both companion animal and livestock products. Turning to the performance of our key brands. In...
4 Large Drug Stocks to Hold on to Amid Industry Challenges
Zacks via Yahoo Finance· 4 days agoDrug and biotech companies are likely to see significant innovation. In the Large-Cap...
Dow Jones Darling Merck Pops As Cancer 'Star' Drives Quarterly Beat
Investor's Business Daily· 3 days agoMerck's bread-and-butter cancer drug grew by double digits again in the first quarter.
